src 32g6 rabbit mab Search Results


96
Cell Signaling Technology Inc rabbit monoclonal anti src
Rabbit Monoclonal Anti Src, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/Src+Rabbit+mAb/pmc08699642-75-3-7
Average 96 stars, based on 1 article reviews
rabbit monoclonal anti src - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc p src
P Src, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/Phospho-Src+Family+(Tyr416)+Antibody/pmc04996535-337-20-28
Average 96 stars, based on 1 article reviews
p src - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit anti src
Rabbit Anti Src, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/Src+Antibody/pmc09396060-219-84-88
Average 96 stars, based on 1 article reviews
rabbit anti src - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc src 32g6 rabbit mab cell signaling technology
Src 32g6 Rabbit Mab Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/Phospho-Src+Family+(Tyr416)+Rabbit+mAb/pm37243482-54-128-132
Average 96 stars, based on 1 article reviews
src 32g6 rabbit mab cell signaling technology - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit anti src mab1
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src <t>mAb1</t> (clone <t>32G6,</t> biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Rabbit Anti Src Mab1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/Rabbit+mAb+IgG+XP+Isotype+Control/pmc10569185-422-6-11
Average 96 stars, based on 1 article reviews
rabbit anti src mab1 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

99
NSJ Bioreagents tnfa antibody
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src <t>mAb1</t> (clone <t>32G6,</t> biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Tnfa Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/TNFa+Antibody/custom%40v2905%4037243593
Average 99 stars, based on 1 article reviews
tnfa antibody - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

94
Bio-Techne corporation desmoglein-3 antibody (5h10)
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src <t>mAb1</t> (clone <t>32G6,</t> biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Desmoglein 3 Antibody (5h10), supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/Desmoglein-3+Antibody+(5H10)/bio-techne+corporation___nbp1-78984
Average 94 stars, based on 1 article reviews
desmoglein-3 antibody (5h10) - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

99
NSJ Bioreagents hsp105 antibody / hsph1
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src <t>mAb1</t> (clone <t>32G6,</t> biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Hsp105 Antibody / Hsph1, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/HSP105+Antibody+%2F+HSPH1/custom%40rq5517%4035820485
Average 99 stars, based on 1 article reviews
hsp105 antibody / hsph1 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
NSJ Bioreagents smn1/2 antibody
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src <t>mAb1</t> (clone <t>32G6,</t> biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Smn1/2 Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/SMN1%2F2+Antibody/custom%40rq4524%4035820485
Average 99 stars, based on 1 article reviews
smn1/2 antibody - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

95
Bio-Techne corporation mouse igg2a isotype control
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src <t>mAb1</t> (clone <t>32G6,</t> biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Mouse Igg2a Isotype Control, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/Mouse+IgG2A+Isotype+Control/bio-techne+corporation___mab003
Average 95 stars, based on 1 article reviews
mouse igg2a isotype control - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

92
Bio-Techne corporation human timp-2 antibody
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src <t>mAb1</t> (clone <t>32G6,</t> biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Human Timp 2 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/Human+TIMP-2+Antibody/bio-techne+corporation___mab971
Average 92 stars, based on 1 article reviews
human timp-2 antibody - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

91
Bio-Techne corporation human/mouse/rat src antibody
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src <t>mAb1</t> (clone <t>32G6,</t> biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Human/Mouse/Rat Src Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src+32g6+rabbit+mab/Human%2FMouse%2FRat+Src+Antibody/bio-techne+corporation___mab3389
Average 91 stars, based on 1 article reviews
human/mouse/rat src antibody - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

Image Search Results


(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .

Journal: Cell reports

Article Title: PhosY-secretome profiling combined with kinase-substrate interaction screening defines active c-Src-driven extracellular signaling

doi: 10.1016/j.celrep.2023.112539

Figure Lengend Snippet: (A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.

(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .

Article Snippet: Anti-c-Src antibodies used for blocking experiments: rabbit anti-Src mAb1 (32G6, biotinylated) (Cell Signaling, #8077), rabbit (DA1E mAb IgG XP Isotype control, biotinylated) (Cell Signaling, #4096), mouse anti-Src mAb2 (Clone 327) (Abcam, #ab16885), rabbit IgG (Abcam, #ab172730), mouse anti-Src mAb3 (L4A1) (Cell Signaling, #2110), rabbit anti-Src mAb4 (36D10) (Cell Signaling, #2109), rabbit anti-Src mAb5 (32G6) (Cell Signaling, #2123), mouse anti-Src mAb6 (clone 327537) (R&D systems, MAB3389), mouse IgG 2A Isotype control (Clone #20102) (R&D systems, MAB003), rabbit pAb (aa 84–110) (custom antibody) (see ).

Techniques: Residue, Phospho-proteomics, Blocking Assay, Sample Prep, Control, Incubation, Recombinant, Western Blot, WST Assay, Proliferation Assay, Concentration Assay, Derivative Assay, Two Tailed Test

Journal: Cell reports

Article Title: PhosY-secretome profiling combined with kinase-substrate interaction screening defines active c-Src-driven extracellular signaling

doi: 10.1016/j.celrep.2023.112539

Figure Lengend Snippet:

Article Snippet: Anti-c-Src antibodies used for blocking experiments: rabbit anti-Src mAb1 (32G6, biotinylated) (Cell Signaling, #8077), rabbit (DA1E mAb IgG XP Isotype control, biotinylated) (Cell Signaling, #4096), mouse anti-Src mAb2 (Clone 327) (Abcam, #ab16885), rabbit IgG (Abcam, #ab172730), mouse anti-Src mAb3 (L4A1) (Cell Signaling, #2110), rabbit anti-Src mAb4 (36D10) (Cell Signaling, #2109), rabbit anti-Src mAb5 (32G6) (Cell Signaling, #2123), mouse anti-Src mAb6 (clone 327537) (R&D systems, MAB3389), mouse IgG 2A Isotype control (Clone #20102) (R&D systems, MAB003), rabbit pAb (aa 84–110) (custom antibody) (see ).

Techniques: Control, Recombinant, Virus, Bradford Assay, Staining, Colorimetric Assay, Software